(ESTA) Establishment Labs Holdings - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.730m USD | Total Return: 92.2% in 12m

Implants, Expanders, Medical Devices
Total Rating 45
Safety 30
Buy Signal -0.65
Medical Devices
Industry Rotation: -4.0
Market Cap: 1.73B
Avg Turnover: 28.7M USD
ATR: 5.66%
Peers RS (IBD): 89.6
Risk 5d forecast
Volatility72.9%
Rel. Tail Risk-9.24%
Reward TTM
Sharpe Ratio1.16
Alpha69.27
Character TTM
Beta1.372
Beta Downside2.758
Drawdowns 3y
Max DD71.43%
CAGR/Max DD-0.09
EPS (Earnings per Share) EPS (Earnings per Share) of ESTA over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.22, "2021-09": -0.61, "2021-12": -0.6, "2022-03": -0.24, "2022-06": -1.52, "2022-09": -0.76, "2022-12": -0.55, "2023-03": -0.48, "2023-06": -0.65, "2023-09": -1.12, "2023-12": -0.79, "2024-03": -0.58, "2024-06": -0.62, "2024-09": -0.59, "2024-12": -1.19, "2025-03": -0.7, "2025-06": -0.57, "2025-09": -0.38, "2025-12": -0.09, "2026-03": 0,
EPS CAGR: 138.71%
EPS Trend: 61.8%
Last SUE: 2.09
Qual. Beats: 1
Revenue Revenue of ESTA over the last years for every Quarter: 2021-03: 30.336, 2021-06: 31.994, 2021-09: 29.039, 2021-12: 35.313, 2022-03: 38.452, 2022-06: 41.19, 2022-09: 38.245, 2022-12: 43.813, 2023-03: 46.524, 2023-06: 48.561, 2023-09: 38.506, 2023-12: 31.56, 2024-03: 37.167, 2024-06: 44.117, 2024-09: 40.227, 2024-12: 44.514, 2025-03: 41.377, 2025-06: 51.3, 2025-09: 53.782, 2025-12: 64.617, 2026-03: null,
Rev. CAGR: 14.85%
Rev. Trend: 53.9%
Last SUE: 0.76
Qual. Beats: 0

Warnings

Interest Coverage Ratio -1.1 is critical

Altman Z'' -2.17 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ESTA Establishment Labs Holdings

Establishment Labs Holdings Inc. (ESTA) is a medical technology company specializing in devices for aesthetic and reconstructive plastic surgeries. The companys primary products are silicone gel-filled breast implants, marketed under the Motiva Implants brand, and breast tissue expanders. The medical device sector often involves rigorous regulatory approval processes.

ESTA distributes its products globally, utilizing both direct sales forces and distributors. This hybrid sales model is common for medical device companies seeking broad market penetration. Their sales span Europe, the Middle East, Africa, Latin America, Asia-Pacific, and North America. Consider exploring ValueRay for further in-depth analysis.

Headlines to Watch Out For
  • Motiva implant sales drive revenue growth
  • Regulatory approvals expand market access
  • Direct and distributor sales network impacts reach
  • Raw material costs influence production expenses
  • Global economic conditions affect elective surgery demand
Piotroski VR‑10 (Strict) 2.5
Net Income: -51.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.16 > 0.02 and ΔFCF/TA 4.95 > 1.0
NWC/Revenue: 79.50% < 20% (prev 105.3%; Δ -25.76% < -1%)
CFO/TA -0.14 > 3% & CFO -51.2m > Net Income -51.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.04 > 1.5 & < 3
Outstanding Shares: last quarter (29.6m) vs 12m ago 2.35% < -2%
Gross Margin: 69.32% > 18% (prev 0.66%; Δ 6.87k% > 0.5%)
Asset Turnover: 59.96% > 50% (prev 47.87%; Δ 12.10% > 0%)
Interest Coverage Ratio: -1.11 > 6 (EBITDA TTM -25.2m / Interest Expense TTM 25.3m)
Altman Z'' -2.17
A: 0.47 (Total Current Assets 249.9m - Total Current Liabilities 82.1m) / Total Assets 357.2m
B: -1.39 (Retained Earnings -495.8m / Total Assets 357.2m)
C: -0.08 (EBIT TTM -28.1m / Avg Total Assets 352.0m)
D: -0.18 (Book Value of Equity -61.2m / Total Liabilities 333.6m)
Altman-Z'' Score: -2.17 = D
Beneish M -2.74
DSRI: 0.94 (Receivables 77.5m/65.0m, Revenue 211.1m/166.0m)
GMI: 0.95 (GM 69.32% / 65.97%)
AQI: 1.31 (AQ_t 0.08 / AQ_t-1 0.06)
SGI: 1.27 (Revenue 211.1m / 166.0m)
TATA: 0.00 (NI -51.1m - CFO -51.2m) / TA 357.2m)
Beneish M-Score: -2.74 (Cap -4..+1) = A
What is the price of ESTA shares? As of April 13, 2026, the stock is trading at USD 60.19 with a total of 348,059 shares traded.
Over the past week, the price has changed by -0.23%, over one month by -5.36%, over three months by -9.84% and over the past year by +92.18%.
Is ESTA a buy, sell or hold? Establishment Labs Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ESTA.
  • StrongBuy: 5
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ESTA price?
Analysts Target Price 88 46.2%
Establishment Labs Holdings (ESTA) - Fundamental Data Overview as of 09 April 2026
P/S = 8.1972
P/B = 72.7138
Revenue TTM = 211.1m USD
EBIT TTM = -28.1m USD
EBITDA TTM = -25.2m USD
Long Term Debt = 247.5m USD (from longTermDebt, last quarter)
Short Term Debt = 14.1m USD (from shortTermDebt, last quarter)
Debt = 264.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 188.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.92b USD (1.73b + Debt 264.5m - CCE 75.6m)
Interest Coverage Ratio = -1.11 (Ebit TTM -28.1m / Interest Expense TTM 25.3m)
EV/FCF = -33.41x (Enterprise Value 1.92b / FCF TTM -57.4m)
FCF Yield = -2.99% (FCF TTM -57.4m / Enterprise Value 1.92b)
FCF Margin = -27.21% (FCF TTM -57.4m / Revenue TTM 211.1m)
Net Margin = -24.19% (Net Income TTM -51.1m / Revenue TTM 211.1m)
Gross Margin = 69.32% ((Revenue TTM 211.1m - Cost of Revenue TTM 64.8m) / Revenue TTM)
Gross Margin QoQ = 70.46% (prev 70.09%)
Tobins Q-Ratio = 5.37 (Enterprise Value 1.92b / Total Assets 357.2m)
Interest Expense / Debt = 2.74% (Interest Expense 7.24m / Debt 264.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -22.2m (EBIT -28.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.04 (Total Current Assets 249.9m / Total Current Liabilities 82.1m)
Debt / Equity = 11.23 (Debt 264.5m / totalStockholderEquity, last quarter 23.5m)
 Debt / EBITDA = -7.49 (negative EBITDA) (Net Debt 188.9m / EBITDA -25.2m)
 Debt / FCF = -3.29 (negative FCF - burning cash) (Net Debt 188.9m / FCF TTM -57.4m)
 Total Stockholder Equity = 25.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.51% (Net Income -51.1m / Total Assets 357.2m)
RoE = -201.8% (Net Income TTM -51.1m / Total Stockholder Equity 25.3m)
RoCE = -10.30% (EBIT -28.1m / Capital Employed (Equity 25.3m + L.T.Debt 247.5m))
 RoIC = -8.34% (negative operating profit) (NOPAT -22.2m / Invested Capital 266.0m)
 WACC = 9.66% (E(1.73b)/V(1.99b) * Re(10.81%) + D(264.5m)/V(1.99b) * Rd(2.74%) * (1-Tc(0.21)))
Discount Rate = 10.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.61%
 [DCF] Fair Price = unknown (Cash Flow -57.4m)
 EPS Correlation: 61.77 | EPS CAGR: 138.7% | SUE: 2.09 | # QB: 1
Revenue Correlation: 53.94 | Revenue CAGR: 14.85% | SUE: 0.76 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.28 | Chg7d=+0.043 | Chg30d=+0.043 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-12-31): EPS=-1.04 | Chg7d=-0.092 | Chg30d=-0.092 | Revisions Net=+1 | Growth EPS=+40.5% | Growth Revenue=+25.7%
EPS next Year (2027-12-31): EPS=0.20 | Chg7d=-0.105 | Chg30d=-0.105 | Revisions Net=-1 | Growth EPS=+119.8% | Growth Revenue=+26.0%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle